Loading…
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $140M | $-361M | $-80M | $-360M | -6.5% | 120.0% | - |
| 2024 | $64M | $-394M | $-377M | $-356M | -51.4% | -83.2% | - |
| 2023 | $378M | $-156M | $-133M | $-183M | -13.5% | 520.0% | - |
| 2022 | $61M | $-316M | $-289M | $-26M | -39.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 60.92 | 377.71 | 63.52 | 139.74 |
| Operating Expense | 399.40 | 554.19 | 479.09 | 523.44 |
| Operating Income | -338.48 | -176.49 | -415.57 | -383.69 |
| EBITDA | -315.90 | -156.47 | -393.64 | -361.40 |
| EBIT | -338.48 | -176.49 | -415.57 | -383.69 |
| Pretax Income | -260.18 | -131.16 | -376.70 | -79.99 |
| Tax Provision | 3.41 | 1.37 | 0.04 | 0 |
| Net Income | -289.09 | -132.53 | -376.74 | -79.99 |
| Net Income Common Stockholders | -289.09 | -132.53 | -376.74 | -79.99 |
| Total Expenses | 399.40 | 554.19 | 479.09 | 523.44 |
| Research And Development | 311.59 | 437.38 | 367.56 | 409.62 |
| Selling General And Administration | 87.81 | 116.81 | 111.53 | 113.82 |
| Normalized EBITDA | -378.91 | -155.12 | -383.41 | -366.22 |
| Normalized Income | -338.86 | -131.46 | -366.51 | -84.81 |
| Basic EPS | -4.13 | -1.72 | -4.58 | -0.81 |
| Diluted EPS | -4.13 | -1.72 | -4.58 | -0.81 |
| Tax Effect Of Unusual Items | 13.23 | -0.28 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0 | 0 |
| Total Unusual Items | 63 | -1.35 | -10.23 | 4.82 |
| Total Unusual Items Excluding Goodwill | 63 | -1.35 | -10.23 | 4.82 |
| Net Income From Continuing Operation Net Minority Interest | -289.09 | -132.53 | -376.74 | -79.99 |
| Reconciled Depreciation | 22.58 | 20.01 | 21.93 | 22.29 |
| Net Interest Income | 15.30 | 46.68 | 49.09 | 43.73 |
| Net Income From Continuing And Discontinued Operation | -289.09 | -132.53 | -376.74 | -79.99 |
| Total Operating Income As Reported | -338.48 | -176.49 | -415.57 | -383.69 |
| Diluted Average Shares | 70.02 | 77.15 | 82.31 | 98.91 |
| Basic Average Shares | 70.02 | 77.15 | 82.31 | 98.91 |
| Diluted NI Availto Com Stockholders | -289.09 | -132.53 | -376.74 | -79.99 |
| Net Income Including Noncontrolling Interests | -289.09 | -132.53 | -376.74 | -79.99 |
| Net Income Continuous Operations | -289.09 | -132.53 | -376.74 | -79.99 |
| Earnings From Equity Interest Net Of Tax | -25.50 | 0 | 0 | 0 |
| Other Income Expense | 63 | -1.35 | -10.23 | 259.97 |
| Special Income Charges | 18.90 | 9.74 | 1.59 | 0.18 |
| Restructuring And Mergern Acquisition | -18.90 | -9.74 | -1.59 | -0.18 |
| Earnings From Equity Interest | 0 | 0 | 0 | 255.15 |
| Gain On Sale Of Security | 44.10 | -11.09 | -11.82 | 4.64 |
| Net Non Operating Interest Income Expense | 15.30 | 46.68 | 49.09 | 43.73 |
| Total Other Finance Cost | -15.30 | -46.68 | -49.09 | -43.73 |
| General And Administrative Expense | 87.81 | 116.81 | 111.53 | 113.82 |
| Other Gand A | 87.81 | 116.81 | 111.53 | 113.82 |
| Operating Revenue | 60.92 | 377.71 | 63.52 | 139.74 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Beam Therapeutics Inc.this co. | BEAM | $3.0B | - | 2.35 | -6.5% | -5.05 |
| LivaNova PLC | LIVN | $3.2B | - | 2.68 | -20.2% | 11.72 |
| Tango Therapeutics, Inc. | TNGX | $3.2B | - | 8.66 | -29.3% | -26.04 |
| Denali Therapeutics Inc. | DNLI | $3.0B | - | 2.87 | -50.6% | -3.93 |
| Alumis Inc. | ALMS | $2.9B | - |
| 7.95 |
| -80.8% |
| -6.02 |
| LifeStance Health Group, Inc. | LFST | $2.9B | 371.50 | 1.90 | 0.6% | 39.06 |
| Dyne Therapeutics, Inc. | DYN | $2.9B | - | 2.95 | -45.9% | -4.14 |
| Erasca, Inc. | ERAS | $2.8B | - | 7.96 | -38.3% | -20.28 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.8B | - | 14.56 | -8.5% | -352.93 |
| Peer Median | - | 371.50 | 5.45 | -33.8% | -5.08 | |